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Cytokines as an Adjuvant to Tumor Vaccines: 
Efficacy of Local Methods of Delivery 
Shuji Kurane, MD, Mmjorie T. Arca, MD, Atsushi Aruga, MD, PhD, Robert A. Krinock, BS, 
John C. Krauss, MD, and Alfred E. Chang, MD 
Background: We examined alternative methods of delivering cytokines as an adjunct for priming 
lymph node (LN) cells draining sites of vaccine inoculation for the purpose of generating immune 
cells for adoptive immunotherapy. 
Methods: Using syngeneic murine tumors we examined the ability of IL-2, IL-4, or GM-CSF 
delivered locally to a site of tumor inoculum to induce antitumor reactive draining LN cells. Mice 
were inoculated subcutaneously with tumor cells transduced to secrete cytokine; tumor cells ad- 
mixed with fibroblasts transduced to secrete cytokine; or intralesional inoculation of cytokine in 
established tumor to induce sensitized LN cells capable of mediating tumor regression in adoptive 
transfer. 
Results: Both IL-4 and GM-CSF cytokines were effective in enhancing the antitumor reactivity 
of vaccine-primed LN cells compared to IL-2, which was ineffective. The local delivery of GM-CSF 
by autocrine or paracrine secretion of genetically engineered cells, as well as direct intratumoral 
delivery was capable of upregulating LN sensitization compared to systemic administration, which 
did not. 
Conclusions: The local delivery of GM-CSF as an adjuvant for tumor vaccination can be 
accomplished by various methods, including direct injection, which avoids the need for gene 
transfer. 
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Several recent developments have caused a resurgence 
of interest in the therapeutic potential of tumor vaccines. 
Foremost among these is our increasing knowledge 
about the cellular events involved in the induction of host 
immunity to tumor antigens. This includes the identifi- 
cation of the key role of dendritic cells necessary to 
process and present antigen (1-3), the requirements for 
co-stimulatory molecules to engage T cells (4-6), and the 
regulatory role of cytokines, which have been classified 
into type 1 versus type 2 effects (7). A second develop- 
ment is the identification of  several human tumor -  
associated antigens that can serve as targets for the im- 
mune system. Many of these tumor-associated antigens 
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appear to be normal molecules that are over-expressed 
by tumor cells, such as HER2/neu in breast, ovarian and 
lung cancer; CEA in colon cancer; or MAGE 1, MAGE 
3, and tyrosinase in melanoma. Mutated oncogenes (e.g., 
Ras) or tumor suppressor genes (e.g., p53) associated 
with carcinogenesis also have been reported to give rise 
to immune responses against the altered gene products 
(8). Several of  these tumor-associated peptides are now 
being used as vaccine reagents in clinical studies. 
The use of  tumor antigens, whether purified peptides 
or derivatives of  whole tumor cells, most likely is more 
effective if coupled with an immune adjuvant. The ear- 
liest observations (by William B. Coley, a surgeon, in the 
1890s) that inoculation of viable bacteria into patients' 
tumors would cause some of them to regress established 
the foundation that the host immune system could be 
modulated in favor of  an antitumor response. Bacterial 
products have been the major immune adjuvants used in 
tumor vaccines for several decades. More recently, the 
identification of  the cytokines as mediators of  the im- 
579 
580 S. KURANE ET AL. 
mune system has given investigators more selective re- 
agents for modulating the antitumor response. In particu- 
lar, the genetic modification of tumor cells to secrete 
different cytokines has been reported to enhance the im- 
munogenicity of tumor cells in syngeneic murine sys- 
tems (9) and has formed the rationale for many current 
gene therapy protocols in cancer patients (10). 
In this study, we used various syngeneic murine tumor 
models to evaluate the efficacy of cytokines IL-2, IL-4, 
and GM-CSF in upregulating host antitumor immunity. 
The primary area we examined was the ability of tumor 
cells and locally delivered cytokines to induce antitumor 
reactive T cells in tumor-draining lymph nodes (TDLN). 
We found that local delivery of cytokines (e.g., GM- 
CSF) by several different methods, as opposed to sys- 
temic administration, was highly effective in eliciting 
antitumor reactivity in TDLN. These observations have 
clinical relevance to the development of tumor vaccines. 
MATERIALS AND METHODS 
Mice 
Female C57BL/6J (B6) mice (Jackson Laboratory, Bar 
Harbor, ME), 6-8 weeks old, were maintained in specific 
pathogen-free conditions and were used for experiments 
at age 8 weeks or older. 
Tumors 
MCA 205 and MCA 207 are fibrosarcomas induced 
by 3-methylcholanthrene in B6 mice. These tumors have 
been previously characterized as immunologically dis- 
tinct (11) and also have been identified as weakly im- 
munogenic by virtue of their ability to induce therapeu- 
tically effective TIL during tumor growth (11) and their 
ability to induce pre-effector lymphoid cells in tumor- 
draining lymph nodes (12,13). Another tumor used in 
this study is the D5 melanoma, a clone of the B16-BL6 
melanoma, which was a spontaneous melanoma that 
arose in a B6 host (14). We have previously character- 
ized the B16~BL6 melanoma as a nonimmunogenic tu- 
mor that does not induce pre-effector lymphoid cells in 
tumor-draining LN (15). 
Recombinant retroviruses 
Plasmid DNA subcloning was carried out by standard 
techniques, using reagents obtained from New England 
Biolabs (Tozer, MA, USA). All the recombinant viruses 
have been described previously (15). pMFG-IL-2 was 
produced by isolating the BamH1 fragment containing 
the routine IL-2 cDNA, and cloned into the BamH1 site 
of pMFG. pMFG IL-4 was produced by isolating the 
BamH1 fl'agments containing the murine IL-4 cDNA and 
cloned into the BamH1 site of pMFG. Murine GM-CSF 
cDNA (a gift from Dr. N. Gough, Melbourne, Australia) 
was mutated to include an Nco 1 site at the initiation of 
ATG and a BamH1 site just 3' to the termination codon 
by polymerase chain reaction, then subsequently cloned 
into the Ncol and BamH1 site of pMFG. Retrovirus 
vectors were co-transfected with the selectable marker 
pSV2Neo into t~ crip cells as described (15). Recombi- 
nant retrovirus producer cell clones were isolated for the 
generation of high-titer viruses and used for transduction 
of tumor cells of cultured fibroblasts. Cytokine-secreting 
tumor clones or fibroblasts were established by transduc- 
ing exponentially growing cells with 5 ml of virus su- 
pernatants in the presence of polybrene (8 p~g/ml), and 
then subcloned by limiting dilution. The NIH 3T3 fibro- 
blast line was obtained from the American Type Culture 
Collection (ATCC, Rockville, MD) for transduction. 
Each clone was screened for cytokine production and 
used in further experiments. 
Cytokine assays 
To evaluate IL-2 secretion from the transduced tumor 
lines, the IL-2-dependent cell line HT-2 (ATCC, Rock- 
ville, MD) was used to determine IL-2 concentration as 
previously described (15). Briefly, 1 ml of medium con- 
ditioned by growing 106 tumor cells for 24 hours was 
assayed for cytokine content in a standard 3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromine 
(MTT) proliferation assay, with recombinant human IL-2 
used as a standard in parallel. To evaluate IL-4 and GM- 
CSF secretion, supernatants were assayed using ELISA 
kits (Pharmingen, San Diego, CA) with recombinant mu- 
rine IL-4 and GM-CSF as a known standard run in par- 
allel. 
Tumor-draining lymph nodes (TDLN) 
Tumor cells in 0.10 ml Hank's balanced salt solution 
(HBSS) were inoculated intradermaUy in the flanks of 
syngeneic B6 mice. Nine to 14 days later, tumor-draining 
lymph nodes from each inoculated mouse were harvested 
under sterile conditions. Lymphocytes were dissociated 
into single cell suspension by teasing apart the LN with 
25-gauge needles and then pressing the LN with the 
blunt end of a 10-ml plastic syringe. 
In vitro anti-CD3/IL-2 activation 
Tumor-draining LN cells were activated for 2 days in 
vitro with immobilized anti-CD3 antibody (145-2Cll 
kindly provided by Dr. J. Bluestone, University of Chi- 
cago, Chicago, IL) in 24-well tissue culture plates at 4 x 
10 6 cells/well. Complete medium (CM) consisted of 
RPMI 1640 medium supplemented with 10% heat- 
inactivated fetal calf serum, 0.1 mM nonessential amino 
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acids, 1 mM sodium pyruvate, 100 mghnl streptomycin, 
1000 U/ml penicillin, 50 mg/ml gentamicin, 0.5 mg/ml 
fungizone (all from GIBCO, Grand Island, NY), and 5 x 
105 M 2-mercaptoethanol (Sigma, St. Louis, MO). After 
anti-CD3 activation, the cells were harvested, washed 
and resuspended at 3 x 105 cells/ml in CM containing 60 
IU/ml of IL-2. Human recombinant IL-2 with a specific 
activity of 18 million IU/mg (Chiron Therapeutics, Em- 
eryville, CA) was used. The cells were subsequently har- 
vested, washed, and resuspended in HBSS for adoptive 
immunotherapy. 
Adoptive immunotherapy protocol 
B6 mice were injected intravenously with tumor cells 
in 1 ml of HBSS to establish pulmonary metastases. On 
day 3, anti-CD3/IL-2 activated LN cells were suspended 
in 1 ml of HBSS and injected intravenously to each 
mouse. Some mice were also treated with 60,000 IU IL-2 
in 0.5 ml HBSS intraperitoneally twice a day for 4 days 
to maintain the in vivo proliferation and antitumor reac- 
tivity of the transferred cells. Approximately 21 days 
after tumor inoculation, the mice were sacrificed and the 
lungs insufflated with a 15% solution of India ink and 
bleached by Fekete's solution (16). Sarcoma pulmonary 
metastases were counted before it was revealed which 
mice had received which treatment. If mice were found 
to be inoculated with D5 melanoma, the lungs were in- 
sufflated with Fekete's solution only to preserve the tis- 
sue for subsequent nodule enumeration. For all experi- 
ments, lungs with pulmonary nodules too numerous to 
count were arbitrarily assigned a value of >250 for sta- 
tistical analysis. 
Statistical analysis 
The significance of differences in the numbers of pul- 
monary metastases between groups was determined by 
Wilcoxon rank-sum test. Two-sided p values of <0.05 
were considered statistically significant. No animals 
were excluded from the statistical analysis. 
RESULTS 
Immune responses induced by tumors genetically 
modified to secrete IL-2, IL-4, or GM-CSF 
Using the MCA 205 tumor, we produced stable clones 
by retroviral transduction that secreted IL-2, IL-4, or 
GM-CSF. The wild-type MCA 205 did not secrete any of 
these cytokines constitutively. IL-2-secreting clones 
named IL-2 (high) and IL-2 (low) secreted 140 and 25 
u/106 cells/24 h, respectively. IL-4 secreting clones 
termed IL-4 (high) and IL-4 (low) secreted 200 and 16 
u / 1 0  6 cells/24 h, respectively. A GM-CSF-secreting 
clone produced 180 ng/106 cells/24 h of transgenic pro- 
tein. The tumorigenicity of these clones was assessed by 
inoculating 3 x 106 tumor cells intradermally in normal 
syngeneic B6 hosts (5 animals/group) and tumor growth 
measured in perpendicular dimensions (Fig. 1). Both 
IL-2 secreting clones were rejected, with the IL-2 (high) 
being rejected earlier. All of these animals developed 
systemic immunity to MCA 205 by their ability to reject 
a subsequent challenge of 107 viable tumor cells. Both 
IL-4 secreting clones manifested reduced tumorigenicity; 
this was greatest with the IL-4 (high) clone. Two of five 
animals inoculated with the IL-4 (high) tumor cells com- 
pletely rejected tumor, whereas the remaining animals 
had barely detectable residual tumor. Mice inoculated 
with GM-CSF-secreting cells did not demonstrate sig- 
nificantly diminished tumorigenicity for the first 21 days. 
After 21 days, one of five animals bearing a tumor mea- 
suring 100 mm 2 went on to completely reject that tumor. 
The other mice became severely cachectic and went on 
to die from apparent toxicity as a result of GM-CSF 
secretion. 
Using our adoptive immunotherapy model, we exam- 
ined the immune reactivity of lymphoid cells derived 
from LN-draining cytokine-secreting MCA 205 tumors. 
Tumor-draining lymph nodes (TDLN) were removed ap- 
proximately 9 to 10 days after intradermal tumor inocu- 
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FIG. 1. Tumorigenicity of trans- 
duced cytokine-secreting MCA 205 
tumors. 3 x 106 tumor cells were 
i nocu l a t ed  i n t r a d e r m a l l y  into 
groups of five mice. Wild-type 
MCA 205 (WT-205) was used as a 
control. Tumors were measured 
twice a week in perpendicular di- 
ameter and a tumor area in mm 2 
was calculated. (A) The growth of 
tumor lines secreting IL-2. (B) Tu- 
mor lines secreting IL-4. (C) The 
growth of tumor cells secreting 
GM-CSF. 
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section. Act iva ted  T D L N  cells were  assessed for their 
ant i tumor react ivi ty  by adopt ive transfer into mice  bear- 
ing micrometas ta t ic  pu lmonary  disease. As summar ized  
in Table  1, the IL-2 (high) c lone of  M C A  205 did not 
enhance  the ant i tumor react ivi ty  of  T D L N  cells when  
compared  to the wi ld- type  tumor. However ,  in a similar  
series o f  exper iments ,  we found that the IL-4 (high) 
c lone o f  M C A  205 did augment  ant i tumor react ivi ty  of  
T D L N  cells in two of  two exper iments  (Table 2). Secre-  
tion of  G M - C S F  by M C A  205 tumor  cells  also enhanced 
ant i tumor react ivi ty  in T D L N  cells (Table 3). 
To further explore  the adjuvant  effect  of  G M - C S F ,  we 
deve loped  several  cytokine-secret ing D5 clones.  These  
D5 clones secreted 400, 150, and 75 ng/106 cel ls /24 h of  
t ransgenic protein. Compared  with the wi ld- type  tumor,  
these clones did not  have  signif icantly altered tumorige-  
nici ty (data not  shown).  In the adopt ive immunotherapy  
model ,  the G M - C S F - s e c r e t i n g  tumor  clones were  found 
to be  ef fec t ive  in the induct ion of  ant i tumor react ivi ty  in 
T D L N ,  whereas  the wi ld- type  D5 tumor  did not (Table 4, 
Exp. 1). The  amount  of  G M - C S F  secret ion was found to 
correlate with the induct ion of  ant i tumor react ivi ty  elic- 
i ted in the T D L N  (Table 4, Exp. 3). 
Local delivery of GM-CSF by 
transduced fibroblasts 
W e  proceeded  to examine  whether  tumor  cells were  
required to secrete G M - C S F  to observe an immune  ad- 
juvan t  effect  or whether  it can be del ivered local ly  by 
another  cell. 3T3 fibroblasts were  retroviral ly t ransduced 
to secrete G M - C S F .  A stable c lone that secreted 50 ng/  
106 cel ls /24h was ident i f ied and used for further experi-  
ments.  T u m o r  cells (D5 or M C A  207) were  mixed  with 
TABLE 1. Treatment of  established MCA 205 lung 
metastases with effector cells generated from LN-draining 
wild-type or IL-2 (high)-secreting MCA 205 
Mean no. of pulmonary 
No. of metastases (SEM) 
Source of cells x 106 
TDLN ceils ~ transferred b Exp. 1 Exp. 2 
None None >250 >250 
Wild-type 6 231 (14) 118 (41) ° 
12 98 (42) ° 71 (34) ~ 
IL-2 (high) 6 222 (18) >250 
12 130 (37) c 225 (16) 
(SEM), (standard error of measurement). 
Mice were inoculated intradermally in the flank with 2-3 x 106 
tumor cells. Tumor-draining lymph nodes (TDLN) were harvested and 
activated in vitro 12 to 14 days later. 
b TDLN cells were transferred intravenously to the mice 3 days after 
intravenous MCA 205 tumor inoculation. All mice received 60,000 u of 
IL-2 intraperitoneally twice a day for 4 days starting on the day of cell 
transfer. 
C p < 0.05 compared to mice not treated with TDLN cells. 
TABLE 2. Treatment of established MCA 205 lung 
metastases with effector cells generated from LN-draining 
wild-type or IL-4 (high)-secreting MCA 205 
Mean no. of pulmonary 
No. of metastases (SEM) 
Source of cells x 106 
TDLN cells a transferred Exp. 1 Exp. 2 
None None >250 >250 
Wild-type 6 153 (44) 105 (19) 
12 91 (22) b 54 (15) b 
IL-4 (high) 6 65 (20) b 61 (20) b 
12 22 (8) b'c 17 (5) b'c 
(SEM), (standard error of measurement). 
a Adoptive immunotherapy protocol is the same as that described in 
Table 1. All mice received 60,000 u of IL-2 intraperitoneally twice a 
day for 4 days starting on the day of cell transfer. 
bp < 0.05 compared to mice with no treatment or treated with IL-2 
only. 
c p < 0.05 compared to mice treated with the same number of wild- 
type TDLN cells. 
equal  numbers  o f  G M - C S F - s e c r e t i n g  fibroblasts and in- 
oculated intradermally into mice.  Nine  days later, T D L N  
cells were  removed ,  act ivated ex vivo,  and assessed for 
an t i tumor  reac t iv i ty  in the adop t ive  i m m u n o t h e r a p y  
model .  As  summar ized  in Table  5, non- t ransduced 3T3 
cells admixed  with D5 tumor  had no adjuvant  effect. 
However ,  G M - C S F - s e c r e t i n g  3T3 manifes ted an adju- 
vant  effect  in the induct ion of  tumor  react ive T D L N  for 
both D5 and M C A  207 tumors.  This demonst ra ted  that 
the paracrine del ivery  of  G M - C S F  was ef fec t ive  in aug- 
ment ing  host  cel lular  immuni ty  against  tumor  and did 
not  require tumor  cells to secrete the cytokine.  
Local delivery of GM-CSF by intratumoral 
inoculation of soluble GM-CSF 
Finally,  we examined  whether  the immune  adjuvant  
effect  media ted  by G M - C S F  could  be induced by the 
TABLE 3. Treatment of established MCA 205 lung 
metastases with effector cells generated from LN-draining 
wild-type or GM-CSF-secreting MCA 205 
Mean no. of pulmonary 
No. of metastases (SEM) 
Source of cells x 106 
TDLN cells ~ transferred Exp. 1 Exp. 2 
None 0 >250 >250 
Wild-type 6 153 (44) 146 (53) b 
12 91 (22) b 15 (13) b 
GM-CSF 6 81 (25) b 27 (15) b 
12 36 (13) bx 0 b 
(SEM), (standard error of measurement). 
a Adoptive immunotherapy protocol is the same as that described in 
Table 1. All mice received 60,000 u of IL-2 intraperitoneally twice a 
day for 4 days starting on the day of cell transfer. 
b p < 0.05 compared to mice not treated with TDLN cells. 
° p < 0.05 compared to mice treated with the same number of wild- 
type TDLN cells. 
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TABLE 4. Treatment of established D5 lung metastases 
with effector cells from LN-draining wild-type or 
GM-CSF-secreting D5 
Mean no. of pulmonary 
metastases (SEM) 
Source of Amount of 
TDLN cells ~ GM-CSF b Exp. 1 Exp. 2 Exp. 3 
None - -  >250 >250 >250 
None - -  >250 >250 >250 
Wild-type 0 >250 ND ND 
D5G6 400 91 (28) c 7 (11) c 29 (26) c 
D5G7 150 ND ND 43 (21) c 
D5G5 75 ND ND 74 (28) c'd 
(SEM), (standard error of measurement). 
a Mice were inoculated intradermally in the flank with 106 tumor 
cells. Nine days later, TDLN were harvested and activated in vitro. 
Seven x 107 TDLN cells were administered intravenously in mice 
bearing 4-day established lung metastases. All mice received 60,000 u 
IL-2 intraperitoneally twice daily for 4 days starting on the day of cell 
transfer. 
bGM-CSF secretion by tumor cells in ng/106 cells/24 h. 
Cp < 0.05 compared to mice not treated with TDLN cells. 
dp < 0.05 compared to mice treated with D5G6 TDLN cells. 
intratumoral  inoculat ion of  cytokine.  This  wou ld  obvia te  
the need  to deve lop  genet ica l ly  modi f i ed  tumor  cells  or 
fibroblasts. To s imulate  amounts  of  G M - C S F  compa-  
rable to a g rowing  inocu lum of  viable  106 D 5 G 6  tumor  
cells  that secrete 400 ng/24 h, soluble cy tokine  was in- 
j e c t ed  in t ra tumora l ly  tw ice  dai ly  at increas ing  doses  
starting on day 1 after intradermal  inoculat ion o f  106 
wi ld- type  D5 tumor  cells. The  total amount  o f  G M - C S F  
del ivered  intratumoral ly per day was: 400 ng (days 1 and 
2); 800 ng (days 3 and 4); 1600 ng (days 5 and 6); and 
3200 ng (days 7 and 8). T D L N  were  harvested on day 9 
TABLE 5. Treatment of  established D5 or MCA 205 lung 
metastases with effector cells generated from LN primed by 
tumor admixed with GM-CSF secreting fibroblasts 
Source of TDLN cells a 
Mean no. of pulmonary 
metastases (SEM) 
D5 (Exp. 1) MCA 207 (Exp. 2) 
A. None 232 (8) >250 
B. Tumor 152 (25) 214 
C. Tumor + 3T3 176 (32) ND 
D. Tumor + 3T3/GM-CSF 44 (9) ° 98 d 
(SEM), (standard error of measurement). 
Mice were inoculated intradermally in the flank with either 106 D5 
(Exp. 1) or 1.5 x 106 MCA 207 (Exp. 2) tumor ceils with or without the 
same number of 3T3 flbroblasts or GM-CSF-secreting fibroblasts 
(3T3/GM-CSF). Nine days later, TDLN were harvested and activated 
in vitro. 
b Mice bearing 3- to 5-day established lung metastases received 2 x 
107 activated TDLN cells intravenously. All mice received 60,000 u of 
IL-2 intraperitoneally twice a day for 4 days starting on the day of cell 
transfer. 
°p < 0.01 compared to groups A, B, and C. 
ap < 0.001 compared to groups A and B. 
and assessed for ant i tumor react ivi ty  in the adopt ive im- 
munotherapy  model .  As  shown in Table  6, intratumoral  
inoculat ion o f  G M - C S F  resulted in the induct ion of  m-  
inor-react ive  T D L N  that was comparab le  to the T D L N  
induced by G M - C S F - s e c r e t i n g  D 5 G 6  cells. To  deter- 
mine  whether  systemic administrat ion of  G M - C S F  can 
have  the same adjuvant  effect  as intratumoral  del ivery,  
the same doses and schedule of  cytokine  were  adminis-  
tered intraperi toneal ly in mice  inoculated with  wi ld- type  
D5 tumor. As summar ized  in Table  6, the intraperi toneal  
administrat ion of  G M - C S F  was not an ef fec t ive  del ivery 
route to induce tumor  react ive T D L N  cells. In this latter 
exper iment ,  D S G 6  tumors were  successful  in the pr iming  
of  sensi t ized T D L N  cells and served as a posi t ive  con- 
trol. 
DISCUSSION 
Using  the weak ly  immunogen ic  M C A  205 sarcoma, 
we  found that t ransduced tumor  cells that e laborated IL-4 
or G M - C S F ,  but  not  IL-2,  resulted in enhanced sensiti- 
zat ion o f  T D L N  cells react ive to tumor.  This  extends our  
previous  observat ions  made  with  the B 16-BL6 tumor, a 
n o n i m m u n o g e n i c  tumor  (17). Both  of  these cytokines  
have  been  reported to be important  in the maturat ion and 
growth of  dendrit ic cells in vitro (18). Dendri t ic  cells  are 
potent  ant igen-present ing cells capable  of  process ing tu- 
mor  ant igen and sensit izing naive  T cells in both in vitro 
and in v ivo  models  (1-3).  W e  hypothes ize  that the ad- 
juvan t  effect  of  IL-4 or G M - C S F  in this mode l  involves  
the recrui tment  or s t imulat ion o f  dendrit ic cells to the 
local  site o f  tumor  ant igen to facil i tate the afferent  arm of  
the i m m u n e  response.  As a he lper  type 1 cytokine,  IL-2 
TABLE 6. Efficacy of systemic versus intratumoral 
administration of GM-CSF to prime D5-draining 
lymph nodes 
Mean no. of pulmonary metastases (SEM) u 
Source of cells a Exp. 1 Exp. 2 
A. None >250 >250 
B. D5 >250 ND 
C. D5 + i.p. GM-CSF >250 ND 
D. D5 + i.t. GM-CSF ND 2 (2) d 
E. D5G6 148 (28) ~ 0 ~ 
(SEM), (standard error of measurement). 
a Mice were inoculated intradermally in the flank with 106 D5 tumor 
cells. GM-CSF was administered intraperitoneally or intratumorally as 
described in the Results section. TDLN were harvested 9 days later and 
activated in vitro. 
b Mice bearing 4-day established lung metastases received 6-7 xl07 
activated TDLN. All mice received 60,000 u of IL-2 intraperitoneally 
twice a day for 4 days starting on the day of cell transfer. 
Cp < 0.05 compared to groups A, B, and C. 
dp < 0.001 compared to group A. 
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acts mainly to promote expansion of antigen-activated T 
cells in the efferem arm of the immune response, and 
hence did not augment the induction of immune TDLN 
cells on a per cell basis. 
Many gene therapy trials in cancer patients are inves- 
tigating the potential of tumor cells genetically modified 
to secrete cytokines as vaccines for active specific im- 
munotherapy in the advanced disease setting in phase I 
trials (10). The likelihood of therapeutic benefit seems 
minimal in this clinical setting. These vaccines ulti- 
mately may prove more useful in the postoperative set- 
ting after patients' primary tumors have been resected 
and they are at risk for micrometastatic disease. Based on 
our animal models, in which we can successfully treat 
advanced, macroscopic disease, we are currently evalu- 
ating GM-CSF-secreting autologous tumor cells as a 
vaccine to prime draining LN cells for adoptive immu- 
notherapy in patients with stage IV melanoma (19). As 
per the animal model, this requires the retrieval of tumor 
tissue and ex vivo genetic engineering of tumor cells to 
express GM-CSF. There can be technical difficulties in 
the culture of tumor cells and successful gene transfer to 
achieve adequate cytokine production; therefore, we and 
others have looked at alternate methods to deliver cyto- 
kines to the microenvironment of tumor cells. 
Fibroblasts are readily cultured from a small sample of 
skin. In our experience, we can establish a fibroblast line 
from human skin in 2 weeks. In this report, we demon- 
strated that allogeneic fibroblasts transduced to secrete 
GM-CSF can be admixed with tumor cells to prime 
draining LN cells. This extends observations made by 
other investigators that cytokine-secreting fibroblasts ad- 
mixed with tumor cells result in altered tumorigenicity 
(20,21). The use of fibroblasts that secrete IL-4 admixed 
with autologous tumor is currently being examined in a 
vaccine trial in melanoma patients (22). 
Another delivery method that we found effective was 
the direct intratumoral inoculation of soluble GM-CSF. 
This approach resulted in comparable priming of TDLN 
cells compared with gene-modified tumor cells. By con- 
trast, the systemic administration of an equivalent dose 
and schedule of GM-CSF was not effective. This under- 
scores the importance of a relatively high concentration 
of the cytokine in the tumor cell microenvironment to 
stimulate an immune response. In a rat model, the co- 
administration of soluble GM-CSF and antigenic peptide 
intradermally was more effective than complete Freund's 
adjuvant mixed with peptide in the induction of anti- 
peptide immunity (23). The use of soluble GM-CSF is 
currently being investigated as an adjuvant for autolo- 
gous tumor cell vaccinations in patients with stage IV 
melanoma. This therapy has resulted in tumor regression 
in a subgroup of patients (24). 
The ability to transfer genes into somatic cells in vivo 
via a variety of different approaches offers opportunities 
to modify established tumors to express cytokines. The 
use of viruses as vectors engineered to introduce cyto- 
kine genes into tumors in vivo has been reported to be 
highly efficient at gene transfer. Viruses that are effec- 
tive for in vivo gene transfer are adenoviruses and the 
pox viruses (e.g., vaccinia) (25). The application of vac- 
cinia virus that contains the gene for GM-CSF is being 
tested as a method for direct intratumoral inoculation in 
patients with melanoma and bladder cancer (26,27). A 
potential impediment to using viral vectors repeatedly in 
the same patient is the development of immunity against 
immunogenic viral epitopes expressed by the vector, 
which may render them less effective. Alternate forms of 
localized in vivo gene transfer that avoid viral vectors 
involve the use of nonviral plasmids encoding the gene 
of interest. Plasmids complexed with liposomes can be 
directly injected into established tumors to accomplish 
successful gene transfer into tumor cells. We have used 
this approach in both animal and human tumor systems 
to stimulate an effective antitumor immune response us- 
ing a foreign major histocompatibility complex class I 
gene (28,29). Another method of transferring plasmids in 
vivo is with the use of a "gene gun." Plasmids attached 
to microgold particles are bombarded onto the tissue tar- 
get to mediate gene transfer. This technique has been 
used in animal models to transfer cytokine genes into 
established tumors with successful tumor regression 
(30). This technique is currently being tested with cyto- 
kine genes in cancer clinical trials (N.S. Yang, personal 
communication). 
In summary, both IL-4 and GM-CSF appear to be 
effective cytokines as adjuvants in tumor vaccines. The 
adjuvant effect depends on the level of cytokine avail- 
able in the local microenvironment of the vaccine. Sev- 
eral different methods of delivering cytokine to the site 
of the vaccine are effective, including local inoculation 
of soluble cytokine. 
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